GH icon

Guardant Health

40.67 USD
+0.21
0.52%
At close May 16, 4:00 PM EDT
After hours
40.67
+0.00
0.00%
1 day
0.52%
5 days
-4.24%
1 month
-9.98%
3 months
-15.74%
6 months
40.44%
Year to date
28.01%
1 year
54.99%
5 years
-56.93%
10 years
26.30%
 

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 2,021

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 14 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

106% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]

29% more capital invested

Capital invested by funds: $2.83B [Q3] → $3.65B (+$819M) [Q4]

10% more funds holding

Funds holding: 267 [Q3] → 295 (+28) [Q4]

7% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 88

5.85% less ownership

Funds ownership: 102.56% [Q3] → 96.71% (-5.85%) [Q4]

48% less call options, than puts

Call options by funds: $29.5M | Put options by funds: $56.8M

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$52
28%
upside
Avg. target
$59
44%
upside
High target
$70
72%
upside

14 analyst ratings

14 positive
100%
neutral
0%
negative
0%
Piper Sandler
David Westenberg
46% 1-year accuracy
21 / 46 met price target
48%upside
$60
Overweight
Maintained
6 May 2025
Scotiabank
Sung Ji Nam
13% 1-year accuracy
3 / 23 met price target
40%upside
$57
Sector Outperform
Maintained
5 May 2025
Canaccord Genuity
Kyle Mikson
39% 1-year accuracy
12 / 31 met price target
60%upside
$65
Buy
Maintained
1 May 2025
Stifel
Daniel Arias
13% 1-year accuracy
2 / 16 met price target
48%upside
$60
Buy
Maintained
1 May 2025
Barclays
Luke Sergott
29% 1-year accuracy
18 / 63 met price target
48%upside
$60
Overweight
Maintained
1 May 2025

Financial journalist opinion

Based on 14 articles about GH published over the past 30 days

Neutral
Business Wire
1 week ago
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2025 Healthcare Conference in Las Vegas, NV Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time Jefferies Global Healthcare Conference in New York, NY Fireside chat on Wednesday, June 4th at 2:35 p.m. Eastern Time Goldman Sachs 46th Annual Global Healthcare Conference in M.
Guardant Health to Participate in Upcoming Investor Conferences
Neutral
Business Wire
1 week ago
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health's list is more than a personal honor,” said AmirAli Talasaz, Guardant Health co-CEO. “It is a recognition of the incredible technology that our Guardant team has buil.
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
Neutral
Business Wire
1 week ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option awards to purchase 19,295 shares of its common stock to two new non-executive employees with a grant date of May 2.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
2 weeks ago
Guardant Health: Tailwinds Are Beginning To Impact The Financials
Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory approval, reimbursement coverage, and study data. I expect Guardant's fundamentals to continue strengthening in coming quarters, which should lead its stock price higher.
Guardant Health: Tailwinds Are Beginning To Impact The Financials
Neutral
Seeking Alpha
2 weeks ago
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Tycho Peterson - Jefferies Bill Bonello - Craig-Hallum Subbu Nambi - Guggenheim Partners Puneet Souda - Leerink Partners Dan Leonard - UBS Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today.
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.46 per share a year ago.
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Neutral
Business Wire
2 weeks ago
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%.
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Neutral
Business Wire
2 weeks ago
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection (MCD) test demonstrated high specificity and clinically meaningful sensitivity across ten tumor types,* while also providing information to guide clinical diagnostic evaluation. The study was presented at the 2025 American Association for Cancer Research (AACR) annual meeting. Results of.
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
Neutral
Business Wire
2 weeks ago
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer genome-wi.
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
Neutral
Business Wire
2 weeks ago
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer. Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced G.
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
Charts implemented using Lightweight Charts™